15 depressive patients and 15 controls, 9 of them age- and sex-matched, were administered 0.2 mg/70 kg i.v. fentanyl, a specific and highly potent µ-opiate receptor agonist. Growth hormone response was significantly reduced in depressive patients in comparison to controls, whereas prolactin response did not significantly differ between the two groups. Cortisol plasma concentration increased in depressive patients and decreased in controls. The difference between the groups failed to reach statistical significance. Only in patients, butnot in controls, fentanyl led to a significant increase in plasma noradrenaline. In contrast, a significant increase in the visual analogue scale for the evaluation of psychotropic drug effects was found only in controls after fentanyl administration. From these preliminary results in connection with other studies we conclude a possible involvement of a disturbed opioid system at least in a subgroup of depressive patients.

Keywords:
Depression, Opiate receptor, Fentanyl, Growth hormone, Prolactin, Cortisol, Noradrenaline, Euphoric response
This content is only available via PDF.
© 1989 S. Karger AG, Basel
1989
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.